In the original publication, the abstract, conclusion was incorrectly published.
Correction to: Clin Drug Investig https://doi.org/10.1007/s40261-017-0615-z
In the original publication, the abstract, conclusion was incorrectly published.
Abstract, Conclusions which previously read: Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy when used as monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.
Should read:
Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy in monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.
The original article was corrected.
The original article can be found online at https://doi.org/10.1007/ s40261-017-0615-z.
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